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ABSTRACT
Objective To evaluate current evidence on the efficacy 
and safety of topical and systemic medications in patients 
with primary Sjögren syndrome (SjS) to inform european 
League Against Rheumatism treatment recommendations.
Methods The MeDLiNe, eMBASe and Cochrane databases 
were searched for case-control/prospective cohort studies, 
randomised controlled trials (RCTs) and systematic reviews.
Results Current evidence in primary SjS patients fulfilling 
the 2002 criteria is based on the data from 9 RCTs, 18 
prospective cohort studies and 5 case-control studies. 
Two Cochrane systematic literature reviews (SLRs) have 
reported that topical treatments for dry mouth and dry eye 
are safe and effective. Ocular cyclosporine A was safe and 
effective in two RCTs including 1039 patients with dry eye 
syndrome. Two Cochrane SLRs on serum tear drops and 
plugs showed inconsistency in possible benefits, both for 
symptoms and objective measures. Five RCTs reported 
significant improvements in oral dryness and salivary flow 
rates for pilocarpine and cevimeline. An RCT showed no 
significant placebo-differences for hydroxychloroquine 
400 mg/day for the primary outcome (visual analogue 
scale (vAS) composite of dryness, fatigue and pain). we 
identified seven RCTs carried out in primary SjS patients. 
RCTs using infliximab, anakinra and baminercept found 
no placebo-differences for the primary outcomes. The 
two largest RCTs randomised 255 patients to receive 
rituximab or placebo and reported no significant results in 
the primary outcome (vAS composite), while prospective 
studies suggested efficacy in systemic disease.
Conclusion The current evidence supporting the use of 
the main topical therapeutic options of primary SjS is solid, 
while limited data from RCTs are available to guide systemic 
therapies.
InTROduCTIOn
Sjögren’s syndrome (SjS), a chronic, systemic 
autoimmune disease, has no cure. Although it 
was identified as a disease more than a century 
ago,1 the therapeutic management has not 
changed significantly in recent decades.2 
The specific pathogenic basis of a disease 
that targets the exocrine glands has led to a 
very specific type of therapy (agents locally 
applied to the mucosal surfaces involved) as 
one of the key approaches. In contrast, the 
systemic element of SjS has traditionally been 
tackled using glucocorticoids (GCs) and 
immunosuppressive agents, due to their use 
in similar systemic diseases such as systemic 
lupus erythematosus or vasculitis.
Key messages
What is already known about this subject?
 ► eULAR has issued the 2019 recommendations for 
the management of Sjögren syndrome.
What does this study add?
 ► The current evidence supporting the efficacy and 
safety of the main topical therapeutic options for 
the treatment of the sicca symptoms of primary 
Sjögren’s syndrome (SjS) is solid.
 ► There is no information on the differential efficacy 
and safety of the main systemic therapeutic options 
available.
 ► Limited data are available from controlled trials to 
guide systemic treatment
How might this impact on clinical practice?
 ► This systematic literature review informed the task 
force for the ‘eULAR recommendations for the man-
agement of Sjögren syndrome’ that will help guide 
practice for physicians from several medical spe-
cialties involved in the management of the disease.
 o
n
 N
ovem
ber 27, 2019 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001064 on 28 O
ctober 2019. Downloaded from
 
2 Brito-Zerón P, et al. RMD Open 2019;5:e001064. doi:10.1136/rmdopen-2019-001064
RMD Open
During the first decade of this century, Food and Drug 
Administration (FDA) approval of muscarinic agents and 
topical cyclosporine A (CyA) for oral and ocular dryness 
in SjS patients, respectively, and the first studies testing 
biological agents were considered the first signs of a new, 
game-changing therapeutic scenario for primary SjS 
patients. Despite this, the first specific systematic litera-
ture review (SLR) of SjS therapy, published in 2010, found 
that evidence remained very limited, without solid results 
that could change the disease management.3 Since 2010, 
there have been significant advances, including the accu-
rate characterisation and scoring of the disease burden,4 5 
the patient-centred therapeutic response6 and the publi-
cation of large, well-designed therapeutic studies.7
The aim of this review was to inform the new EULAR 
recommendations on the current state of evidence on 
the efficacy and safety of the main topical and systemic 
therapies used in SjS.
MeTHOds
A MEDLINE SLR was carried out by PB-Z and SR using 
the MeSH term ‘Sjögren’s syndrome’ combined with 
each therapeutic intervention proposed by the Task 
Force (see ‘Intervention’ section of the Population, 
Intervention, Comparison, Outcomes and Study design 
(PICOS) strategy) with the following restrictions: date (1 
January 1986 to 31 December 2017), studies (humans) 
and age (adults). Additional databases, such as EMBASE 
and Cochrane Central Library, were also checked. The 
SLR strategy followed prespecific PICOS definitions 
agreed by the Steering Committee members: (a) Popula-
tion: in order to collect evidence from an aetiopathogen-
ically homogeneous population, data was retrieved from 
studies including adult primary SjS patients fulfilling 
the 2002 criteria (stated in the manuscript as ‘primary-
2002’ patients) or the 2016 ACR/EULAR criteria8 9; (b) 
Intervention: using the data from a 2010 SLR as a starting 
point,6 10 interventions were classified as topical or 
systemic medications; (c) Comparison: therapeutic inter-
ventions were compared with placebo (PLA) or other 
therapeutic interventions; (d) Outcomes: eligible studies 
had to contain sufficient, clear information on the effect 
of the therapeutic intervention (efficacy) and on the 
safety profile; (e) Study design: we included randomised 
controlled trials (RCTs), cohort studies (prospective 
non-PLA-controlled, non-randomised studies and those 
with quasi-experimental designs), case-control studies 
(comparing therapeutic options) and meta-analyses, 
according to the definitions proposed by the Oxford 
Centre for Evidence-Based Medicine (CEBM),11 while 
case series (descriptive/retrospective therapeutic studies) 
were considered in the absence of other studies; narrative 
reviews, experimental animal studies, duplicate publi-
cations and isolated case reports were excluded. In the 
absence of evidence on the target population, extrapola-
tion of results from studies including SjS populations that 
differed from the definition in the PICOS strategy was 
allowed. Figure 1 summarises the SLR results. Summary-
of-finding tables were generated for RCTs (table 1),10 12–19 
prospective cohort studies (table 2)20–37 and case-control 
studies (table 3).38–42 For RCTs, the risk of bias (RoB) 
was assessed using the Cochrane RoB assessment tool 
(Cochrane Handbook for Systematic Reviews of Interven-
tions V.5.1.0 March 2011 (available from: http:// hand-
book. cochrane. org/)), and for uncontrolled studies, we 
used the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement checklist. 
The few RCTs available for each therapeutic intervention, 
together with the heterogeneity in the methodology of 
the studies included, such as differing participant char-
acteristics, comparative interventions, the small size of 
the populations studied and the differences in follow-up 
intervals and outcomes measured, make it impossible to 
pool data in a meta-analysis.
ResulTs
Oral topical therapies
Saliva substitutes
We identified five studies that evaluated gels/saliva substi-
tutes in SjS patients, of which only one was carried in 
primary-2002 patients38: Alpöz et al found that Xialine 
(a saliva substitute containing polysaccharide xanthan 
gum plus sodium fluoride) and plain water plus diluted 
tea (serving as PLA) were equally effective in most VAS 
scoring for specific oral symptoms, with the only between-
group differences being an increased preference for 
Xialine at the end of the study (p=0.011). A Cochrane 
SLR evaluated the effectiveness of topical treatments for 
any-cause dry mouth (including SjS) in parallel and cross-
over RCTs using lozenges, sprays, mouth rinses, gels, oils, 
chewing gum and/or toothpastes and found no strong 
evidence supporting any one specific topical therapy as 
more effective in treating dry mouth.43
interferon alpha
Three studies have evaluated the use of interferon alpha 
per the oromucosal route in SjS patients fulfilling the 
1993 criteria, including a large RCT of nearly 500 patients 
that found significant improvement only in unstimulated 
salivary flow (uSF), with a higher percentage of gastroin-
testinal adverse events in comparison with PLA.3
Ocular topical therapies
Artificial tear drops
Seven studies testing artificial tears (ATs) in patients 
with SjS were identified, all of which found significant 
improvements with respect to baseline in both VAS ocular 
dryness and diagnostic tests (except in one study) with no 
reported side effects.3 Only one study,39 comparing the 
use of AT with plug insertion, was carried out in primary-
2002 patients: no significant between-group differences 
were reported and, after 8 weeks of treatment, patients 
treated with AT showed significant improvement in all 
ocular diagnostic tests performed (p<0.001). A recent 
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Figure 1 Flow chart of the systematic literature review. PICOs, Population, Intervention, Comparison, Outcomes and Study 
design; RCTs, randomised controlled trials; SjS, Sjögren’s syndrome; SLRs, systematic literature reviews.
Cochrane review of AT drops for dry eye syndrome 
concluded that ATs are safe and effective.44
Non-steroidal anti-inflammatory drugs/GC-based tear drops
Evidence is overwhelmingly limited to studies including 
patients with associated SjS or non-2002 SjS patients. Only 
one study40 was carried out in primary-2002 patients, and 
this compared topical 0.1% fluorometholone (FML) with 
topical CyA: although no significant differences were 
detected between groups for the main efficacy param-
eters (except for tear breakup time (BUT), with better 
results in the FML group), although patients treated with 
topical 0.1% FML showed significant improvements with 
respect to baseline in the Corneal Fluorescein Staining 
score (p<0.001), BUT (p<0.001) and Ocular Surface 
Disease Index (p<0.001) after 8 weeks of therapy, but 
not for the Schirmer test; no serious side effects were 
reported: the mean intraocular pressure change at 8 
weeks was +0.4 mm Hg in the FML group versus −1.15 mm 
Hg in the CyA group (p=0.389).
Cyclosporine-based tear drops
In December 2002, an ophthalmic formulation 
containing 0.05% CyA was approved by the US FDA to 
treat dry eye disease at a recommended two times per day 
dose, based on the results of two RCTs that included 1039 
patients with keratoconjunctivitis sicca (SjS patients were 
included in varying proportions).3 Since then, a summary 
of the results reported until now shows that most studies 
only demonstrated within-group improvements, and 
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those that reported significant between-group differ-
ences (drug and vehicle) found improvement in only 
one to two of the four to eight ocular outcomes evalu-
ated.45 In addition, a study extension trial found no addi-
tional improvement in subjective and objective meas-
urements after 6 months of therapy.46 With respect to 
adverse events, the largest RCT47 found that most events 
were mild-to-moderate and transient, with a significantly 
higher percentage of burning eye in comparison with 
PLA (15% vs 6% in PLA), and only 2% of patients discon-
tinued because of burning and stinging.3
There are no specific RCTs in primary-2002 patients, 
with only one case-control study, the above-mentioned 
study by Lin and Gong,40 which showed no significant 
differences with topical 0.1% FML and with a higher 
frequency of moderate-to-severe transient burning sensa-
tion in patients receiving CyA.
Tacrolimus-based tear drops
A recent small RCT using 0.03% tacrolimus tear drops 
in 24 SjS 2002 patients found significant improvements 
in the Schirmer test and corneal staining (fluorescein, 
rose Bengal) after 3 months of therapy in comparison 
with drops that included only the vehicle. Nearly 80% of 
those receiving tacrolimus experienced a burning sensa-
tion after instillation.48
Serum tear drops
Autologous serum (AS) has been tested in six small (<30 
patients) uncontrolled studies in SjS patients and has 
shown inconsistent benefits (improvement in some but 
not all ocular tests performed).49 Only one study was 
carried out in primary-2002 patients, which showed a 
significant improvement with respect to baseline in three 
out of five ocular outcomes.41 A recent Cochrane review 
of AS for dry eye syndrome49 confirmed inconsistency in 
the possible benefits of AS for both symptoms and objec-
tive measures, with no evidence of an effect after 2 weeks 
of treatment.
insertion of lachrymal plugs
Of the nine studies identified in SjS patients, only 
two were carried out in p2002-SjS patients. Qiu et al39 
compared the insertion of plugs with ATs in 40 patients: 
both treatments improved all ocular outcomes (subjective 
and objective) without statistically significant between-
group differences. In a prospective study, Egrilmez et al20 
reported improvement in two out of four ocular tests 
with respect to baseline 12 months after inserting plugs. 
A recent Cochrane SLR reviewed the use of plugs for dry 
eye syndrome50 and found that the evidence was very 
limited and improvements in symptoms and ocular tests 
were inconclusive.
Diquafosol
In 2004, an ophthalmic formulation of diquafosol (an 
agonist of the purinergic P2Y receptor) was tested by 
Tauber et al51 in an RCT including 527 patients with 
dry eye (only 76 had SjS), which reported statistically 
significant differences between groups in only one of the 
two defined primary outcomes, with no further studies 
being reported, making it impossible to recommend 
their use.
Oral muscarinic agonists
Two muscarinic agonists (pilocarpine and cevimeline) 
were licensed by the FDA in 1998 and 2000, respectively, 
for the treatment of oral dryness in SjS patients; these 
agents stimulate the M1 and M3 receptors present on 
salivary glands, leading to increased secretory function.
Pilocarpine
The two pivotal RCTs included 629 SjS patients (fulfilling 
the 1993 criteria and including both primary and asso-
ciated cases) and found significant improvements in 
oral dryness VAS and salivary flow rates at doses of 5 and 
7.5 mg/6 hours in comparison with the PLA arm.3 The 
RCTs showed a high frequency of adverse events, including 
sweating (43%), increased urinary frequency (10%) 
and flushing (10%). In a dose-escalating RCT, nearly a 
quarter of patients reduced from 7.5 to 5 mg/6 hours 
in a second 6-week period of therapy. Only two studies 
have been carried out in primary-2002 patients, and only 
one assessed efficacy. In a prospective study, Aragona et 
al21 reported a significant improvement with respect to 
baseline in oral dryness VAS (p<0.001) after 2 months of 
therapy with pilocarpine 5 mg/6 hours.
Cevimeline
Three RCTs including 332 SjS patients (fulfilling the 
1993/Japanese criteria, both primary and associated 
cases) tested the use of cevimeline using dosages ranging 
between 15 and 60 mg/8 hours. The best results were 
achieved with a dose of 30 mg/8 hours, including signifi-
cant improvements in dry mouth and salivary flow rates, 
with a significantly higher frequency of nausea (relative 
risk 1.68) and sweating (relative risk 2.16) in comparison 
with PLA.3 There is only one study carried out in primary-
2002 patients, but there was no information detailed 
about overall efficacy and safety.30 Only one study has 
compared cevimeline with pilocarpine but only assessed 
the safety profile. Noaiseh et al42 retrospectively analysed 
118 primary-2002 patients and found a lower failure rate 
of cevimeline both in first-time (27% vs 47%, p=0.02) and 
all (32% vs 61%, p<0.001) users in comparison with pilo-
carpine. Severe sweating was the main reason for therapy 
cessation and occurred more frequently in pilocarpine 
users (25% vs 11%, p=0.02).
Hydroxychloroquine
We identified 12 studies that assessed hydroxychloro-
quine in SjS patients, with only 4 (2 prospective and 2 
RCTs) carried out in primary-2002 patients. Yavuz et al31 
prospectively enrolled 32 patients treated with hydroxy-
chloroquine for at least 2 years (no data on mean length 
or cumulative dose) and reported, in a further 12-week 
control study, a significant improvement in four out of 
eight ocular outcomes with respect to baseline, with no 
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information on concomitant ocular therapies. Çankaya 
et al32 prospectively evaluated 30 women who started on 
400 mg/day of hydroxychloroquine and reported a signif-
icant improvement in uSF rate (0.212 vs 0.162 baseline, 
p<0.05) but not stimulated salivary flow rate at 30 weeks, 
with improvement in only two of the five subjective oral 
VAS scores. Yoon et al17 carried out a small RCT in 26 
patients and found no significant differences in dry eye 
in comparison with PLA, but with no definition of the 
primary outcome.17 The pivotal RCT was carried out by 
Gottenberg et al16 in 120 patients with primary-2002 SjS 
who were randomised to receive 400 mg/day of hydroxy-
chloroquine (n=56) or PLA (n=64): the primary outcome 
was defined as a ≥30% reduction in two out of three VAS 
scores—dryness, fatigue, pain—without significant PLA 
differences at week 24 (17.6% vs 17.3%, p=0.96). For one 
of the secondary outcomes, hydroxychloroquine was asso-
ciated with a statistical trend to improved pain (p values 
between 0.06 and 0.10 at 12, 24 and 48 weeks) although 
it was not superior to PLA for articular involvement; with 
respect to fatigue, no statistical differences were found.16 
No cases of retinal toxicity or severe adverse events were 
reported in any of these studies.
Oral GCs
The frequent use of GCs in clinical practice in primary SjS 
patients is not supported by reliable scientific evidence. 
In the absence of controlled studies in 2002 patients, 
we briefly analysed the data in other SjS populations.3 
The first study was a very small RCT (eight patients per 
arm) comparing prednisone 30 mg/day with piroxicam 
20 mg/day and PLA, which found significant differ-
ences in subjective symptoms but not in objective tests.52 
However, a prospective study of 60 patients followed for a 
mean of nearly 4 years found that corticosteroids did not 
influence the progressive decrease in salivary flow rates.53 
No controlled studies are published in primary-2002 
patients, and only retrospective studies have reported 
the use of GCs for systemic disease,54 with a high rate of 
GC-related adverse events, including increased appetite 
and weight gain,52 a two-fold higher frequency of diabetes 
mellitus55 56 and Cushing in up to 80% of patients.56
Immunosuppressive agents
Seven studies have tested immunosuppressive agents in 
SjS patients (two studies using leflunomide and cyclo-
phosphamide, respectively, and one study each for azathi-
oprine, methotrexate and mycophenolate), of which 
only two were carried out in primary-2002 patients. van 
Woerkom et al27 carried out a prospective study using 
20 mg/day of leflunomide, which showed significant 
improvement in 5 out of 16 efficacy parameters tested 
after 24 weeks of therapy (2 were components of quality 
of life (QoL) questionnaires and 3 analytical parame-
ters); all 15 patients experienced adverse events (between 
4 and 8 per patient), principally gastrointestinal (67%), 
cytopenia (47%) and lupus-like cutaneous lesions 
(33%). Willeke et al28 tested the use of micophenolic acid 
1440 mg/day, reporting significant improvement in 8 
out of 16 efficacy parameters after 24 weeks of therapy, 
including VAS for sicca features (p<0.02) and mean AT 
use (p<0.02) (other parameters that improved included 
components of QoL questionnaires and analytical param-
eters); adverse events were reported in 72% of patients.
Biological therapies
Of the 34 studies in which biological agents have been 
tested in SjS patients, we identified 6 RCTs (using inflix-
imab (INF), anakinra and rituximab) and 10 prospec-
tive cohort studies (using etanercept, abatacept, epratu-
zumab, rituximab and belimumab) carried out in 
primary-2002 patients. A summary of the results of the 
efficacy parameters is provided in table 4.
Abatacept
Two small prospective cohort studies have tested abat-
acept in primary-2002 patients. The first enrolled 15 
patients with early active disease who received eight intra-
venous abatacept infusions24 and reported that ESSDAI, 
EULAR Sjogren’s Syndrome Patient Reported Index 
(ESSPRI), rheumatoid factor and IgG levels decreased 
significantly at 48 weeks; fatigue and health-related 
quality of life parameters improved significantly, while 
salivary and lacrimal gland function did not change; 6 
(40%) patients experienced mild acute adverse events 
and 10 (67%) self-reported infections. The second 
study included 11 patients and reported increased saliva 
production (1.74 vs 1.61 g/2 min baseline, p=0.029) after 
24 weeks of therapy and decreased lymphocytic foci in 
total (but not lymphocytic foci per mm2); one patient 
developed lupus-like cutaneous lesions.25
Anakinra
A small RCT that randomised 26 patients (13 to anakinra 
and 13 to PLA) found no significant reduction in fatigue 
in the primary endpoint14 (comparison of fatigue scores 
at week 4, p=0.19); 2 patients experienced severe side 
effects (injection site reaction and gastroenteritis, respec-
tively), 2 had a transient episode of neutropenia and 7 
(54%) mild injection site reactions.
Baminercept
St Clair et al18 have recently reported on the clinical 
efficacy and safety of baminercept in 52 patients with 
primary-2002 randomised in a 2:1 ratio to receive subcu-
taneous injections of 100 mg of baminercept every 
week for 24 weeks or matching PLA. The primary end 
point was the change between screening and week 24 
in the stimulated whole salivary flow (SWSF) rate. The 
change from baseline to week 24 in the SWSF rate did 
not differ significantly between the baminercept and the 
PLA groups (baseline-adjusted mean change −0.01 vs 
0.07 mL/min; p=0.332). Baminercept was associated with 
a higher incidence of liver toxicity, including two serious 
adverse events.
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Belimumab
The results reported by the Efficacy and Safety of Beli-
mumab in Subjects with Primary Sjögren’s Syndrome 
(BELISS) open-label trial57 in 30 primary-2002 patients 
(all with systemic complications, early disease and/or 
abnormal biomarkers) showed that belimumab 10 mg/kg 
(weeks 0, 2 and 4, and then every 4 weeks until week 24) 
was associated with a higher rate of improvement in the 
composite outcome (improvement of at least two of the 
five following items: ≥30% reduction in VAS for dryness, 
fatigue, musculoskeletal pain and physician systemic 
activity, and ≥25% reduction in any of the B-cell activation 
biomarkers) in patients with early disease in comparison 
with those with systemic disease (73% vs 47%); the mean 
ESSDAI score decreased from 8.8 to 5.59 (p<0.0001) and 
the ESSPRI score from 6.44 to 5.56 (p=0.01). In the 19 
patients who completed 1 year of treatment, a significant 
improvement in some ESSDAI involvements (glandular, 
lymphadenopathy and articular) was maintained.22 With 
respect to the safety profile, only one serious adverse 
event was reported (pneumococcal meningitis) after six 
drug infusions.
epratuzumab
In 2006, a small prospective study including 15 patients 
with primary-2002 SjS23 reported a beneficial effect on 
VAS fatigue (<0.05), patient assessment (<0.05), physi-
cian assessment (<0.05) and tender joints (<0.05); five 
patients experienced severe adverse events (acute infu-
sion reactions and infections).
etanercept
Two studies (one RCT, one prospective) have been 
carried out in SjS patients; only the prospective study 
included primary-2002 patients and showed no signif-
icant improvements in the main sicca signs and symp-
toms.29
infliximab
A prospective open-label study in 16 patients found signif-
icant improvements in subjective and objective measures 
after the administration of INF, although recently the 
authors have retracted the manuscript.58 In 2004, Mari-
ette et al12 conducted an RCT including 103 patients and 
found no significant differences in the primary outcome, 
defined as improvement in at least 30% of the joint pain, 
fatigue and dryness VAS at 22 weeks (INF 20.4% vs PLA 
16.7%, p=0.62) or in the majority of secondary outcomes 
(symptoms, salivary flow rates, ocular tests, QoL and sali-
vary biopsy), with improvement only in fatigue and some 
analytical parameters in comparison with PLA.
Rituximab
Rituximab has been tested in three prospective cohort 
studies,33–35 one case-control study36 and four RCTs.10 13 15 19 
A summary of the significant improvements reported with 
respect to baseline in the prospective cohort studies 
showed improvement in VAS for dryness,34 36 fatigue34–36 
and pain/tender point count,34 while no significant 
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improvements were reported for objective oral and 
ocular tests (except in the study by Pijpe et al33 in a subset 
of patients). In the case-control study, Carubbi et al36 
compared the therapeutic effect of rituximab (n=22) and 
conventional immunosuppressive therapy (n=19) and 
found a significant improvement in patients treated with 
rituximab in the ESSDAI (<0.05), global VAS (<0.05), 
fatigue VAS (<0.01), dryness VAS (<0.01), physician VAS 
(<0.05), uSF (<0.01) and Schirmer test (<0.05) at the end 
of follow-up (120 weeks); the authors reported a complete 
lack of reported adverse events in either of the two arms 
in spite of the long-term nature of the study. With respect 
to the two small RCTs, Dass et al13 randomised 17 primary-
2002 patients to receive rituximab (n=8) or PLA (n=9) 
and found no significant results in the primary outcome 
(improvement >20% VAS fatigue at 6 months, rituximab 
87% vs PLA 56%, p=0.36), while Meijer et al10 randomised 
30 primary-2002 patients to receive rituximab (n=20) or 
PLA (n=10) with no significant results for the primary 
outcome (improvement in SWSF rate at 48 weeks, 
p>0.05). Two large RCTs have recently been reported. In 
2014, Devauchelle-Pensec et al15 randomised 122 primary-
2002 patients to receive rituximab (n=63) or PLA (n=57) 
and found no significant results in the primary outcome 
(≥30 mm improvement at week 24 on at least 2 out of 4 
VAS scores—dryness, fatigue, pain, global, 23% vs 22%, 
p=0.91), while Bowman et al19 randomised 133 primary-
2002 patients to receive rituximab (n=67) or PLA (n=66) 
and found no significant results in the primary outcome 
(reduction ≥30% at week 48 in either fatigue or oral 
dryness VAS, rituximab 39.3% vs PLA 36.8%, p=0.76). 
Two recent meta-analyses including the four RCTs have 
confirmed the lack of significant between-group differ-
ences in mean improvements between baseline and week 
24 values for fatigue VAS, oral dryness VAS, salivary flow 
rate and Schirmer test, and no significant difference 
between groups for the main adverse events.59 60
dIsCussIOn
Current evidence on the therapeutic management of 
primary-2002 SjS patients is based on 9 RCTs (only four 
including ≥100 patients randomised to drug/PLA), 18 
prospective cohort studies (all including ≤30 patients per 
study) and 5 case-control studies.
For oral topical therapies, available evidence is limited 
to five studies carried out in SjS patients (only one in 
primary-2002 patients) and one Cochrane SLR that 
assessed the management of dry mouth. Xerostomia is 
a subjective symptom with wide interindividual variation, 
and a satisfactory output of unstimulated whole saliva in 
one patient may lead another to complain of symptoms of 
dry mouth. All studies have shown significant within-group 
improvement in comparison with baseline subjective oral 
outcomes. Mechanical stimulation (chewing gum) was 
associated with increased saliva production in patients 
with residual capacity, but there is no evidence that gum 
may have more or less efficacy than saliva substitutes in 
reducing dry mouth symptoms. Due to the wide range of 
interventions, small trials (mean of 45 participants per 
trial), the RoB and the range of outcome measures for 
oral dryness, there is no strong evidence to support any 
specific intervention over another, and the conclusion is 
that, in the absence of an effective topical treatment, we 
recommend that the treatment of xerostomia should be 
directed towards improving patients’ complaints rather 
than increasing saliva production, including improve-
ments in tooth health and the prevention of oral infec-
tions. The cost of long-term topical therapy is another 
important consideration, but there are no available 
studies on this issue. Other therapeutic interventions 
are under investigation. A recent double-blind, cross-
over-design study has evaluated the effects of intraoral 
electrostimulation,61 and further studies in primary-2002 
patients are required to make a specific recommendation 
on its use.
For ocular topical therapies, among the 43 studies in 
SjS patients, only 6 (14%) were carried out in primary-
2002 patients, while there are 4 SLRs on the management 
of dry eye using ATs, AS and plugs.44 49 50 62 The Cochrane 
SLR on AT showed that the AT formulations tested 
improved the signs and symptoms over the course of 
the studies included, although they found no consistent 
between-group differences when conducting head-to-
head AT comparisons. The authors concluded that, given 
the large number of AT formulations compared and 
the wide variety of outcomes, it was difficult to propose 
that one over the counter AT formulation is superior to 
another for the treatment of dry eye syndrome. However, 
AT consistently improved ocular symptoms over the 
course of the trials included, based on within-group anal-
yses, and three of four PLA-controlled trials consistently 
found that AT improved ocular symptoms compared 
with PLA (saline or vehicle), with a similar trend for 
many of the secondary outcomes. This review also 
found that the use of ATs is relatively safe, with the most 
common adverse events being blurred vision, ocular 
discomfort and foreign body sensation. It is important to 
consider that most outcomes were subjective measures 
of patient-reported outcomes rather than objective 
outcomes.44 With respect to non-steroidal anti-inflamma-
tory drug (NSAID)/GC-based ocular tears, evidence not 
including primary-2002 SjS patients suggests careful use 
of tears containing NSAIDs or GCs due to the side effects 
associated with prolonged use.63 In these patients, ocular 
topical NSAIDs or corticosteroids may be a short-term 
therapeutic approach prescribed by ophthalmologists for 
the minimum time necessary (maximum 2–4 weeks).63
With respect to topical CyA, the pivotal study (a combi-
nation of two trials including 877 patients—270 fulfilled 
the 1993 SjS criteria, not detailed how many were 
primary or associated) evaluated 14 efficacy outcomes 
(4 objective, 10 subjective) with no definition of which 
were primary or secondary and found statistically signif-
icant differences between groups only in 4 (2 subjective 
and 2 objective). In spite of this, the FDA approved their 
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use. In addition, a review of the results of all reported 
studies shows that most studies only demonstrated with-
in-group improvements, and those that reported signif-
icant between-group differences (drug and vehicle) 
found improvement in only 20%–30% of the outcomes 
evaluated.45 In addition, a study extension trial found 
no additional improvement in subjective and objec-
tive measurements in patients treated for >6 months.46 
Although SjS patients were included in variable propor-
tions in the above-mentioned RCTs, there are no RCTs 
specifically in primary-2002 patients.64 Only one recent 
prospective study was made in primary-2002 patients, 
which found no significant differences between topical 
CyA and topical 0.1% FML.40 A recent small RCT using 
0.03% tacrolimus tear drops found significant improve-
ments in 24 primary-2002 patients48; the lack of defini-
tion of the population included (unclear whether they 
were primary or associated cases), the high rate of side 
effects and, especially, the limited number of cases does 
not support their widespread use in primary SjS patients, 
although they could be considered as a rescue therapy 
for CyA non-responders/intolerant patients.
With respect to AS and plug insertion, in addition to the 
very limited evidence available for primary-2002 patients, 
the two Cochrane SLRs found significant limitations in 
the quality of trials (incomplete descriptive statistics for 
reported treatment outcomes, sample sizes with too few 
participants, quasi-randomisation methods, complete 
masking may not have been feasible, short-term evaluation 
of efficacy, lack of details on adverse outcomes and toler-
ance). For AS, the Cochrane SLR concluded that current 
evidence suggests that 20% AS might provide some benefit 
in improving patient-reported symptoms over the short 
term (2 weeks), but longer periods of follow-up provide no 
evidence of improvement over longer periods, while no 
clear effects were found for objective clinical measures of 
the ocular surface. For punctal occlusion, the certainty of 
the evidence ranged from moderate to very low (frequently 
downgrading the level of evidence due to the high RoB or 
imprecision in effect estimates), and it was concluded that 
current evidence suggests that punctal plugs are a modestly 
effective means of treating dry eye. For all these reasons, 
the use of AS and plugs in primary SjS has been considered 
as a rescue therapeutic option, always under prescription 
by an ophthalmologist. A combination of AS and plugs 
has recently been evaluated65 in 28 SjS patients (primary 
and associated, criteria not detailed). Ophthalmologists 
play a key role in prescribing topical and systemic thera-
pies for ocular dryness, always with a close multidisciplinary 
follow-up.
The two pivotal trials of pilocarpine included 629 patients 
with primary/associated SjS fulfilling the 1993 criteria and 
reported statistically significant differences between groups 
for the two primary VAS outcomes defined. With respect 
to cevimeline, the two pivotal trials included 272 patients 
with primary/associated SjS fulfilling the 1993 criteria 
and reported statistically significant differences between 
groups for the primary VAS outcomes. There is very limited 
evidence to support the use of these drugs in the treatment 
of oral dryness in primary-2002 patients (only one study 
using pilocarpine). It would seem appropriate to offer 
patients a trial of the drug, assuming there are no contrain-
dications (ie, uncontrolled asthma, uncontrolled chronic 
obstructive pulmonary disease, uncontrolled cardiorenal 
syndrome, acute iritis, pregnancy, breast feeding) to the 
use of the drug. The trial should be prolonged, since the 
response can be delayed (up to 12 weeks), with a recom-
mended dose of 5 mg three times a day to keep side effects 
to a minimum, since the adverse effects are dose depen-
dent. Additional studies are required to clarify the role 
of muscarinic agonists in the treatment of xerostomia in 
primary SjS patients.
With respect to systemic synthetic immunosuppressive 
drugs, there are no new studies specifically assessing GCs 
in primary SjS in the last 20 years. For immunosuppressive 
agents, all reported studies (all including <20 patients) 
were principally centred on the efficacy in sicca features 
(with limited benefits) and laboratory parameters, with 
no specific analysis of the outcomes recommended in the 
guidelines (efficacy in systemic disease) and with an unac-
ceptable rate of adverse events (41%–100%).3 In addition, 
there is a lack of head-to-head studies comparing the effi-
cacy and safety profile of the different immunosuppressive 
agents.
The emergence of biological therapies has increased 
the therapeutic armamentarium available to treat SjS, 
but their use is limited by the lack of licensing. Available 
evidence is principally supported by the studies testing 
rituximab in primary SjS, making this drug the most 
frequently tested in these patients. There are six addi-
tional prospective cohort studies including ≤30 patients 
(one for etanercept, two—one extension—for belim-
umab, one for epratuzumab and two for abatacept), one 
small study (<30 patients) using anakinra, one medi-
um-sized study (n=52) using baminercept and one large 
trial (>100 patients) using INF.
The results of trials on the efficacy of rituximab in 
the outcomes evaluated are summarised in the SLR 
published by Letaief et al.59 There were no statistically 
significant differences between groups for the primary 
outcomes based on subjective VAS dryness. The quality 
of evidence according to the Grades of Recommenda-
tion Assessment, Development and Evaluation (GRADE) 
approach was low for oral dryness, salivary flow rates, 
fatigue, mental health and ESSDAI meta-analysis and 
moderate for the Schirmer test meta-analysis. All studies 
included reported adverse effects, but with no significant 
differences between groups; the meta-analysis presented 
low-quality evidence according to the GRADE approach. 
The promising results obtained in small uncontrolled 
studies for the use of belimumab and abatacept should 
be confirmed in large RCTs before a solid therapeutic 
recommendation for use in primary SjS patients in stan-
dard clinical practice can be made. Limited data have 
been obtained from controlled trials to guide systemic 
treatment, although prospective studies using rituximab 
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have suggested efficacy in systemic disease, especially in 
cryoglobulinemic vasculitis, as reported in unselected 
cryoglobulinemic patients.66
The current evidence supporting the efficacy and safety 
of the main topical therapeutic options for the treatment 
of sicca symptoms of primary SjS is solid but is extrap-
olated from the results of RCTs carried out in mixed 
populations of patients with dryness caused by SjS and 
other aetiologies. The overall low level of evidence from 
therapeutic studies specifically carried out in primary 
SjS patients fulfilling the current classification criteria 
underscores the need for considerably larger trials. In 
addition, there is no information on the differential effi-
cacy and safety of the main systemic therapeutic options 
available and treatment-by-treatment choices will remain 
challenging in clinical practice.
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